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Cancer is a leading cause of death worldwide; 
approximately 14.1 million new cancer cases and 8.2 
million cancer-related deaths were recorded globally in 
2012 [1].  Ageing is the biggest risk factor for cancer, 
and the majority of tumours are diagnosed in patients 
older than 60 years [2,3]. The World Health 
Organization predicts that the proportion of the world’s 
population over the age of 60 will almost double from 
12% to 22% between 2015 and 2050 (World Health 
Organization, 2015). The evolving age demography 
affects cancer incidence and mortality rates,  which  has  
 
serious consequences for a country’s healthcare system 
and economy [4,5]. Novel insights into the age-related 
genetic predisposition of cancer survival would be a 
major breakthrough in expanding healthy life span in 
humans. 
 
The last decade has seen extensive efforts to catalogue 
human genetic variation [6,7] and to correlate variation 
with phenotypic traits. For example, single nucleotide 
polymorphisms (SNPs) have been assessed for 
statistical associations with complex traits such as 
longevity [8–14] and various common diseases [15–22]. 
Case-control studies that compare population SNP 
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The World Health Organization  predicts  that  the  proportion  of  the  world’s  population  over  60 will  almost
double from 12% to 22% between 2015 and 2050. Ageing is the biggest risk factor for cancer, which is a leading
cause of deaths worldwide. Unfortunately, research describing how genetic variants affect cancer progression
commonly neglects  to account  for  the ageing process. Herein  is  the  first systematic analysis  that combines a
large longitudinal data set with a targeted candidate gene approach to examine the effect of genetic variation
on  survival  as  a  function  of  age  in  cancer  patients.  Survival was  significantly  decreased  in  individuals with
heterozygote  or  rare  homozygote  (i.e.  variant)  genotypes  compared  to  those  with  a  common  homozygote
genotype  (i.e.  wild  type)  for  two  single  nucleotide  polymorphisms  (rs11574358  and  rs4147918),  one  gene
(SIRT3)  and  one pathway  (FoxO  signalling)  in  an  age‐dependent manner. All  identified  genes  and  pathways
have  previously  been  associated  with  ageing  and  cancer.  These  observations  demonstrate  that  there  are
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frequency to disease characteristics often simply list a 
set of SNPs statistically significantly associated with a 
particular condition, not accounting for the ageing 
process. Unfortunately, this is an oversight, as 
molecular systems affected by such genetic variants are 
evolving entities whose interactions change with age 
[23,24]. For example, the ageing process affects 
multiple inter-linked molecular systems including the 
immune [3,25,26], metabolic [27,28] and cardiovascular 
[29] systems. 
 
Ageing affects cancer incidence rates [30,31], prognosis 
[32–34] and drug response [35]. Recently, Kulminski et 
al. (2014) investigated the effects of the e4 allele of the 
APOE gene on human survival in a range of ages from 
mid-life until extreme old age, and the sensitivity of 
those effects to cardiovascular disease, cancer and 
neurodegenerative disease [12]. This allele is thought to 
have a protective effect against early life infectious 
disease such as diarrhea and liver damage caused by 
Hepatitis C virus infection. Their research suggested 
that, although there is an advantage to the allele in early 
life, there is a significant adverse effect of the e4 allele 
on survival that is limited to women with a moderate 
lifespan (70-95 years). Furthermore, non-skin cancer 
increased the risk of death of e4 carriers two-fold 
compared to non-e4 carriers among women of moderate 
lifespans. These observations suggest the existence of 
age- and gender-sensitive systemic mechanisms linking 
the e4 allele to lifespan that can non-additively interfere 
with cancer-related mechanisms. The research described 
herein combines the availability of a large longitudinal 
data set with a targeted candidate gene approach to 
examine the effect of genetic variation on survival as a 
function of age from a systematic perspective. Insights 
obtained from this novel investigation are of high 
biological importance, as understanding the biomarkers 
and molecular mechanisms that affect cancer prognosis 
in an age-dependent manner will provide critical 
information for age-specific patient outcome and 
relevant assignment to therapies; an area of research 





Data set assembly and quality filtering: phenotypic 
and genotypic data 
 
The population under study in this analysis is the 
Framingham Heart Study (FHS). In brief, the FHS 
comprises >10,000 individuals in different cohorts who 
have been examined every 2-4 years for up to 60 years 
(depending on cohort; see Methods). The FHS has 
previously successfully addressed interesting biological 
questions related to ageing and disease [11,12,37,38]. 
Using FHS data, two cancer data sets were assembled 
based on tumour topography for all patients that were 
first diagnosed with cancer over the age of 50; all 
except skin cancer (AESC; n=1,194) and all except skin 
and sex cancer (AESSC; n=867) (Table S1a).  Survival 
was defined as the length of time (in years) between 
initial diagnosis and death. In this study, all-cause 
mortality is being considered. Survival data was 
organised into: full data set (i.e. those diagnosed aged 
50+), and three age categories: individuals diagnosed 
between the ages of 50 and 64, diagnosed 65 and 79, 
and those diagnosed aged 80 plus. Herein, we focus on 
the larger data set, AESC; however, the results for 
AESSC are also described in the supplementary 
material. Unless otherwise stated, the results for the two 
data sets were similar, with the exception that the 
smaller AESSC data set tended to lose statistical power 
more quickly.  In addition to cancer survival data, we 
also collected information about tumour grade, co-
morbidities, sex, cohort and familial relationships for 
each individual, in order to consider the impact that 
these factors have on survival (see Methods). 
 
The FHS Affymetrix 50K Human Gene Focused 
microarray was employed in this study. There were 
36,647 SNPs remaining after a quality filtering and 
linkage disequilibrium (LD) analysis (see Methods). 
The primary objective of our analysis was to identify 
polymorphisms and corresponding molecular 
mechanisms that affect survival in an ageing-related 
manner. Thus, we used the commonly implemented 
approach that focuses on SNPs that are in close 
proximity to known longevity associated genes (LAGs) 
[42,61–64]. A set of 316 putative longevity associated 
genes (LAGs) was assembled (Table S1d); and 880 
SNPs located near/within 245 of the 316 longevity 
associated genes were extracted for analysis. The 
commonly used dominant genotypic model was 
employed, in which the heterozygous and variant 
homozygote genotypes were combined into a single risk 
group (the “variant”/ “Var” group) and compared to the 
common homozygote (the “wild type”/ “WT” group) 
[12,68,69].  
 
Subsequently, we conducted a gene-level analysis by 
examining the 245 genes that the 880 SNPs that had 
been assigned to in the previous paragraph (Table S1e). 
A LAG could have (1) One SNP per gene,  (2) Two 
SNPs per gene or (3) More than two SNPs per gene. For 
the “one SNP per gene” category, each individual was 
classified as possessing either the wild type or variant 
genotype at the SNP position.  For the “two SNPs per 
gene” category, each individual was classified 
depending on the combination of wild type and variant 
alleles that they possessed at each SNP position; 
“WT_WT” (i.e. wild type at first SNP position and wild 
www.aging‐us.com  2119  AGING 
type at second SNP position) or “WT_Var”, “Var_WT” 
or “Var_Var”. For the “more than two SNPs per gene” 
category, individuals were classed as having a low 
(<33%), medium (34-65%) or high (>66%) number of 
wild types. Each gene was assigned to an age-related 
KEGG pathway, where possible. Individuals were 
described as either having a low (<50%) or high (>50%) 
number of wild type SNPs per pathway. In total, 880 
SNPs were assigned to 245 aging-related genes and 18 
pathways.  
 
To identify differences in survival patterns in different 
genotypes for a set of ageing-related variants between 
different diagnosis age brackets, we conducted a 
survival analysis, comprising (1) Kaplan Meier (KM) 
Estimator and (2) Cox Proportional Hazards Model.  A 
Kaplan Meier Curve constructs a survival curve to 
compare the survival patterns of two or more groups of 
individuals, and a Log Rank Test is subsequently 
implemented to examine the null hypothesis that there is 
no difference between the populations in the probability 
of an event (in this case, death) occurring at a time 
point. A Kaplan Meier Curve and Log Rank Test cannot 
account for any other possible confounding factors that 
may affect survival, and so a Cox Proportional Hazard 
Regression Model subsequently modelled survival as a 
function of other variables, including genotype, sex, 
comorbidity status, cancer grade and cohort. Data sets 
were then divided by sex, cohort, and equal numbers of 
genotypes to examine the robustness of both the Kaplan 
Meier and Cox Model analyses. The reader is directed 
to the exact number of individuals used in each analysis 
at relevant times throughout the manuscript. 
 
There is one SNP (rs11574359), two genes (GPX4 and 
SIRT3) and one pathway (FoxO) that demonstrated age-
related patterns of survival in cancer patients and will 
be discussed in turn.  For each SNP, gene and pathway 
of interest, the results are laid out as a description of: (1) 
Kaplan Meier Curve, (2) Kaplan Meier Curve using 
sub-sets of the data (i.e. using equal numbers of 
genotypes, and dividing the data set by sex and cohort), 
(3) Cox Model and (4) Cox Model results once the 
model is adjusted for co-variates of interest rather than 
stratified, and once the data set is split by sex and 
cohort. 
 
Rs11574358, a non-synonymous SNP in the WRN 
gene, has an age-dependent impact on mortality in 
cancer patients 
 
A Kaplan Meier analysis was conducted for each of the 
880 SNPs assigned to LAGs (Table S2a for full output 
from Kaplan Meier analysis for all SNPs). Four SNPs 
consistently demonstrate significant (FDR < 0.05) 
survival differences between the wild type and variant 
genotypes in different age categories (Table S2b): 
rs1794108, rs4147918, rs11574358 and rs317913.  In 
all of these cases, possessing the wild type confers a 
longer survival time.  In this section, we will focus on 
one SNP, rs11574358, the only SNP whose survival 
differences between genotypes in an age-dependent 
manner remained significant after the implementation of 
the Cox Model. However, it is interesting that the other 
SNPs significant from the Kaplan Meier analysis (i.e. 
rs1794108, rs4147918 and rs317913) are all located 
within well-known cancer and ageing related genes. For 
example, rs1794108 is a missense deleterious mutation 
in the proteasome 26S subunit, non-ATPase 13 
(PSMD13) that is involved in cellular senescence [85], 
ageing [86] and with the onset of various cancers [87–
89]. ABCA7, the gene that rs4147918 is located within, 
is on chromosome 19p13.3, the same chromosomal 
section as APOE, a gene that is well known to be 
associated with ageing and longevity related traits 
[21,90,91].  ABCA7 has also been implicated recently in 
cancer progression; [92,93]; the SNP itself has also 
been previously associated with Alzheimer’s Disease 
[94]. Finally, rs317913 is located within the ral guanine 
nucleotide dissociation stimulator-like 3 gene (RGL3). 
Both the SNP [95,96] and the gene have previously 
been identified with cancer-related traits [97].  
 
In the Kaplan Meier analysis; for rs11574358, in the full 
data set (i.e. those diagnosed 50+), the WT genotype 
patients have a significantly longer 5-year survival rate 
(5YSR) than those with the variant (Var) genotype 
(5YSR: WT: 70.1% (95% CI: 67.2-72.9%), Var: 40.1% 
(95% CI: 31.8-50.6%), FDR= 3.45E-12). Similar 
significant survival differences are observed in those 
diagnosed 50 to 64 (FDR= 3.0E-4) and diagnosed 65 to 
79 (FDR= 1.16E-7), but not in the diagnosed 80 plus 
age bracket (FDR= 0.85) (Fig. 1, Table S2b). 
 
A number of analysis repetitions were conducted to 
ensure the robustness of the observations; these are 
described in further detail in the Methods.  First, in each 
of the age categories, an equal number of wild type and 
variant genotypes were randomly extracted, and the 
analysis was repeated, statistically significant survival 
patterns (FDR < 0.01) observed in all age groups except 
those individuals diagnosed over the age of 80 (Table 
S3a1). However, in this case, although the number of 
individuals is constant between the genotypes within 
each age category, there are still different numbers of 
individuals between the age categories. Thus, for the 
larger AESC data set, 20 individuals were subsequently 
elected at random for each genotype for all age 
categories, and the analysis was repeated; this ensures 
that the number of individuals remains constant per 
genotype both within and between all age categories. 
The Log Rank P Values are significant different in both 
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those diagnosed 50 to 64 (P=3.94E-03) and those 
diagnosed 65 to 79 (P=2.41E-03) (Table S3a). Dividing 
the AESC data set up by sex and cohort, statistically 
significant (FDR <0.05) survival differences are still 
observed in all the age categories except those 
diagnosed over 80 in the offspring (Table S3c) cohort, 
and in males (Table S3d) and females (Table S3e); and 
in the full data set and those diagnosed 65 to 79 in the 
original cohort (Table 3b). Thus, we suggest that the 
differences in survival patterns between the wild type 
and variant genotypes between the different age 
categories cannot be easily explained by the effects of 
cohort, sex or sample size. 
 
The genotypic and phenotypic distribution of the data 
set used in the Cox Model is found in Table S3f. After 








































cohort, comorbidities, tumour grade at diagnosis and 
familial relationships, different survival patterns are still 
observed in all of the age categories except those 
diagnosed over the age of 80. The hazard ratio of the 
risk allele in the full data set (i.e. diagnosed 50+) is 1.95 
(95% CI: 1.47-2.58; FDR= 2.64E-05) indicating that 
those individuals with the variant genotype (i.e. 
heterozygous or rare homozygote) have a 1.95-fold 
increased risk of death compared to those that possess 
the wild type (common homozygote). The HR increases 
to 4.65 (95% CI: 2.56-8.43; FDR= 6.01E-06) in the 
diagnosed 50 to 64 age category, and decreases to 2.81 
(95% CI: 1.77-4.46; FDR= 2.57E-04) for those 
diagnosed 65 to 79 (Table 1, Table S3g). There are no 
significant survival differences in those individuals 
diagnosed >80 (FDR= 0.98). The Cox Model analysis 









































Figure 1.  Kaplan Meier  survival  estimates  of  overall  cancer  survival  for  rs11574358  among  the  Framingham Heart
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robustness of observations; as described in the Methods. 
First, the same significant age-dependent effects on 
survival as described are observed by adjusting the Cox 
model co-variates instead of stratifying (Table S3h). 
Second, significant or marginally significant survival 
differences in the same age categories are still observed 
once the data set is separated by sex (Females: Table 
S3i; Males: Table S3j) and offspring cohort (Table S3l) 
and in those diagnosed 65 to 79 in the original cohort 
(Table S3k), or if an equal number of individuals 
(AESC: N=176; AESSC: N=119) are randomly selected 
from each age category and the analysis is repeated 
(Table S8a). 
 
 Rs11574358 is a non-synonymous SNP in the Werner 
(WRN) gene converting a serine to an alanine. SIFT, a 







































substitutions based on the degree of conservation of 
amino acid residues based on alignments of closely 
related sequences [98] predicts that this variant is 
deleterious to protein function.  
 
Rs4147918 in GPX4, and SIRT3, display patterns of 
age-dependent differences in mortality 
 
Each of the 880 SNPs in the analysis was assigned to a 
gene ±60kb of the SNP. There are 60 genes with one 
SNP assigned to the gene, 54 genes with two SNPs 
assigned to the gene, and 131 genes with more than two 
SNPs assigned to the gene (Table S1f). The full set of 
Kaplan Meier results for the gene analysis is in Table 
S2c.  There was one gene of interest with two SNPs per 
gene; glutathione peroxidase 4 (GPX4) that had two 









































the  minor  homozygote.  The  full  data  set  indicates  all  individuals  diagnosed  with  cancer  over  the  age  of  50;  and
subsequently  each  age  category  is  the  individuals  diagnosed with  cancer  in  that  particular  age  category.  Solid  lines
indicate survival curve, dashed line indicates 95% confidence interval. 
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analysis, there are significantly different survival 
differences between the genotypes in both the full data 
set (FDR= 0.046) and in those diagnosed 65 to 79 
(FDR= 0.013). In these two age categories, the average 
5YSR for those with a WT allele in the first SNP 
position (i.e. a WT_WT or WT_Var genotype) is at 
least 17% higher than those with a variant allele in the 
first position (i.e. a Var_WT or Var_Var genotype; Fig. 
2, Table S2d). There are no statistically significant 
differences in survival between genotypes for those 
diagnosed 50 to 64, or those diagnosed 80 plus (FDR=> 
0.05). To examine the effects of sample size on the 
observations, 20 individuals were subsequently 
randomly selected from each of the genotypes per age 
category and the analysis was repeated (Table S4a). 
Similar to earlier observations, there are no statistically 
different survival patterns between the genotypes in any 






































Val = 0.03). Similar observations were made once the 
data set is divided by sex (Males: Table S4b, Females: 
Table S4c) and in the original cohort once the data is 
divided by cohort (Table S4d) but not in the offspring 
cohort (Table S4e).  
 
The genotypic and phenotypic distribution of the data 
set used in the Cox Model is in Table S4f. In the 
“diagnosed 65 to 79” age category, possessing the 
“Var_WT” genotype led 1.85-fold increased risk of 
death compared to the “WT_WT” genotype (95% 
CI=1.24-2.74; FDR = 0.02). In all other age categories 
of the AESC data set, there was no statistically 
significant difference in survival between genotypes 
(Table S4g, Table 1). A similar pattern is observed 
when variables are adjusted for rather than stratified in 
the Cox model (Table S4h) and pre-FDR significance is 














































N in KM 
analysis 
HR 95% CI P Value FDR 
SNP Analysis          
rs11574358 TT GT+GG WRN 50+  1,133 1.95 1.47-2.58 2.83E-06 2.64E-05 
    50-64 378 4.65 2.56-8.43 6.40E-02 6.01E-06 
    65-79 558 2.81 1.77-4.46 8.65E-01 2.57E-04 
       80+ 197 1.16 0.56-2.17 0.27 0.98 







1,035 1.25 0.94-1.47  0.12 0.48 
    50-64 351 1.32 0.54-3.22 0.53 0.82 
    65-79 504 1.85 1.85 (1.24-
2.74) 
2.3E-3 0.02 
       80+ 180 1.40 0.72-2.69 0.32 0.74 






1,037 1.49 1.06-2.03 0.02 0.09 
    50-64 353 1.23 0.59-2.56 0.57 0.81 
    65-79 501 1.98 1.21-3.21 0.007 0.06 
       80+ 183  1.02 0.51-2.01 0.96 0.96 
Pathway 
Analysis 
         






1,146 1.13 0.85-1.51 0.39 0.39 
    50-64 382 1.31 0.72-2.38 0.37 0.39 
    65-79 564 1.90 1.13-3.11 0.014 0.058 
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S4i, Females: Table S4j) and in the Original cohort 
(Table S4k), but not the Offspring cohort (Table S4l). A 
similar observation of age-dependent survival 
differences between allele combinations with marginal 
significance is made in both the AESC (N=347) and the 
AESSC (N=287) data sets if an equal number of 
individuals is randomly selected from all age categories; 
Table S8b). Thus, the age dependent effects of this gene 
are not easily explainable by sample size, cohort, sex, 
familial relationship or tumour characteristic effects. 
 
The data suggests that having a variant allele at the first 
position (rs4147918) and a wild type allele at the 
second position (rs757232) leads to an increased risk of 
death for patients with cancer in an age-dependent 









































this data set. Thus, although the SNPs were technically 
assigned to GPX4, rs4147918 (i.e. the variant) is located 
in the nearby ABCA7 gene, while rs757232 (the wild 
type) is in Histocompatibility (Minor) HA-1 gene 
(HMHA1). Rs757232 did not display significantly 
different survival patterns after the KM analysis in the 
individual SNP analysis (Table S2a). However, 
rs4147918 significantly affects survival in an age-
dependent pattern in the SNP-level KM analysis (Full 
Data set FDR = 1.54E-04, Diagnosed 65 to 79= 9.51E-
06; Table S2b) and is located within a known cancer 
and ageing related gene, as described in the previous 
section.  
 
A second gene of interest is NAD-dependent 










































dominant genotype model,  comparing patients with a high number of wild  types  to  those with a  low number of wild
types. The  full data  set  indicates all  individuals diagnosed with cancer over  the age of 50; and  subsequently each age
category is the individuals diagnosed with cancer in that particular age category. Solid lines indicate survival curve, dashed
line indicates 95% confidence interval. 
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assigned four SNPs: rs11246007, rs11246020, 
rs1794108 and rs2280544. Each individual is 
characterised depending on the number of wild type 
alleles: “low” (one), “medium” (two) or “high” (three or 
four) number of wild type alleles. In SIRT3, possessing 
a high number of wild types led to at least 20% longer 
5YSR in both the full data set (FDR=8.8E-07) and those 
diagnosed 65 to 79 (FDR=8.8E-07; Fig. 3, Table S2e).  
 
Similar to previous sections, the effects of sample size 
were considered by randomly selecting 20 individuals 
from both wild type and variant genotypes for each of 
the age categories and repeating the analysis, thus 
ensuring that the number of individuals per genotype is 
constant both within and between all age categories. In 
agreement with our observations, there were no 
statistically significant survival differences in any of the 
age categories except marginal significance for those 
diagnosed between the age of 65 and 79 (Log Rank P 
Val = 0.09; Table S5a). Similar age-dependent survival 
differences between genotypes for this gene are 
observed if the data set was divided by cohort (Original 
Cohort: Table S5b, Offspring Cohort: Table S5c) or sex 
(Males: Table S5d, Females: Table S5e). 
 
The genotypic and phenotypic distribution of the data 
set used in the Cox Model is found in Table S5e. After 
conducting a Cox Model analysis, individuals with a 
low number of wild types that were diagnosed 65 to 79 
have a 1.98-fold (95% CI=1.21-3.21; FDR= 0.06) 
increased risk of death compared to those with a high 
number of wild type alleles (Table S5g). A similar 
observation are consistently observed if one adjusts for 
the co-variates rather than stratifies (Table S5h), and 
similar significant or pre-FDR significant or marginally 
significant (in the case of original cohort) pattern is 
observed once the data is split by cohort or sex (Tables 
S5i-S5l). Similar patterns are found with marginal 
significance in the AESSC data set if an equal number 
of individuals (N= 119) is selected from each age 
category and the analysis is repeated; and in both AESC  
(N=347) and AESSC (N=287) data sets if equal 
numbers of individuals are randomly selected from the 
full data set, those diagnosed 50 to 64 and those 
diagnosed 65 to 79 age categories (Table S8). 
 
SNPs were allowed to be ±60kb of a gene in this data 
set. Rs11246007 is an intron variant in SIRT3. 
Rs11246020 is a missense mutation in SIRT3 that 
converts a valine to an isoleucine. Rs2280544 is a UTR 
Variant 3’ SNP in the BET1 Golgi Vesicular Membrane 
Trafficking Protein Like (BET1L) gene. Interestingly, 
rs1794108 is one of four SNPs that consistently 
demonstrated survival differences in the initial Kaplan 
Meier SNP analysis, as described earlier (Table S2a).  
 
SNPs in the FoxO pathway display age-dependent 
patterns of mortality 
 
Six of the eighteen putative ageing-related pathways 
(Rap1 signalling, FoxO signalling, Cell Cycle, p53 
signalling, Fc epsilon signalling and TNF signalling) 
displayed marginally significant  (FDR < 0.10) survival 
differences in the KM analysis between two genotype 
groups (i.e. having a low and high number of wild 
types) in different age groups (Table S2f). Un-
surprisingly, these pathways are known to be involved 
in cancer-related processes; e.g. p53 signalling, Cell 
Cycle and Rap1 signalling (Table S2f). There is one 
pathway of interest after the Cox Model that will be 
discussed in detail: FoxO signalling. There 29 genes 
(Table S6a) and 108 SNPs (Table S6b) assigned to the 
FoxO pathway. In the KM analysis, there is 
significantly different survival patterns observed in 
those diagnosed 65 to 79 (FDR=0.058; Fig. 4, Table 
S2g).  In this case, having a high number of wild type 
alleles confers a protective effect on survival.  Unlike 
all of the other SNPs and genes, the same pattern is not 
replicated once equal numbers individuals per genotype 
per age category are extracted and the Kaplan Meier 
analysis is repeated (Table S6c). In the diagnosed 65 to 
79 age category, significantly different survival 
patterns between genotypes are observed in the 
original cohort (Table S6d) and in females (Table S6g) 
but not in the offspring cohort (Table S6e) or in males 
(Table S6f).  
 
The genotypic and phenotypic distribution of the data 
set used in the Cox Model is in Table S6h.  After the 
Cox model, possessing a low number of wild types 
leads to 1.90 (95% CI: 1.13-3.11; FDR=0.058) 
increased risk of death compared to possessing a high 
number of wild types in those diagnosed 65 to 79 (Table 
S6i; Table 1). Subsequently, a similarly significant 
increased hazard ratio is observed for those with a low 
number of wild type alleles in the diagnosed 65 to 79 
age category if the Cox model is adjusted for co-
variates rather than stratified (Table S6j), and similar 
pre-FDR significance is observed if the analysis is 
conducted on each sex separately (Table S6k, S6l) and 
in original cohort (Table S6m), but not in the offspring 
cohort (Table S6n). Post-FDR significantly different 
survival is also observed in the AESC (N=349) and 
AESSC (N=139) data sets if an equal number of 
individuals are selected from each age category and the 
analysis is repeated (Table S8d). The three most 
common types of the effects for the SNPs in the FoxO 
pathway are intron variants (38%), non-coding 
transcript variants (17%) and mis-sense variants 
(11%). 
 








































Replication of results in an independent population 
 
A replication population was selected based on the 
combination of two cohorts; Atherosclerosis Risk in 
Communities Study and Cardiovascular Health Study; 
the assembly of these data sets is described in detail in 
the methods. We attempted to replicate our results in 
this combined replication population; however the 
Framingham Heart Study is quite unique; both in terms 
of the large amount of data collected over a long period 
of time and the SNPs that were genotyped on its unique 
custom Human Gene Focussed Affy 50K array. 
Unfortunately, although this replication population has 
been invaluable in the past in investigating various traits 
associated with ageing and longevity (for example, 
[12,99]), there was a low overlap in the SNPs (16 SNPs) 








































way analysis in this study and the ARIC/CHS arrays. 
Only two SNPs of interest could be considered further 
in our analysis; however, rs11574358; a key SNP of 
interest in our analysis had a minor allele frequency of 0 
in both the ARIC and CHS data sets and so could not be 
considered further. Thus, the replication study purely 
focussed on rs4147918 (MAF of 0.036 and 0.044 in 
CHS and ARIC, respectively).  
 
For rs4147918, 92% (N=1,808) of the data set was 
assigned as wild type (i.e. homozygous dominant for 
this polymorphism), while 8% (N=140) were con-
sidered as variants. The cancer phenotype available for 
this study in ARIC/CHS included cancers at all sites 
because there was no information on cancer without 
skin in ARIC. Comorbidity phenotype was defined as 
the score counting presence of the following diseases in 
Figure 4.  Kaplan Meier  survival  estimates  of  overall  survival  for  FoxO  pathway  among  the  Framingham Heart  Study
according  to  a dominant  genotype model,  comparing patients with  a high number of wild  types  to  those with  a  low
number  of  wild  types.  The  full  data  set  indicates  all  individuals  diagnosed  with  cancer  over  the  age  of  50;  and
subsequently  each  age  category  is  the  individuals  diagnosed with  cancer  in  that  particular  age  category.  Solid  lines
indicate survival curve, dashed line indicates 95% confidence interval. 
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an individual (each disease was coded as 1; no disease 
was coded as 0): heart failure, diabetes, stroke, and/or 
myocardial infarction. A Kaplan Meier analysis 
indicated that there were significantly different survival 
patterns only in the Full Data set (P=0.03) and not in 
any of the specific age categories, although the 
difference was marginally significant in those diagnosed 
65 to 79 (P=0.06; Table S7). Thus, there were no 
significant results of note after the Cox Model and the 
relationship between survival between the different age 
categories could not be considered using this population 




The investigation described herein is the first systematic 
study to address how the ageing process impacts the 
effect that single nucleotide polymorphisms have on 
cancer survival; a field that could greatly affect the 
possibility of individualising cancer prognoses and 
treatments in the post-genomic era. There were two 
SNPs (rs11574358 and rs4147918), one gene (SIRT3) 
and one pathway (FoxO signalling) that may be of 
interest for further consideration.  
 
Rs11574358 is a non-synonymous SNP in the Werner 
(WRN) gene. WRN is responsible for the progeroid 
Werner Syndrome, characterised by the accelerated 
appearance of features associated with ageing [100–
102]. This syndrome is well established to be associated 
with an elevated risk of cancer [103,104].  Some of the 
most common co-occurring chronic co-morbidities 
among cancer patients include ischemic heart disease, 
hypertension and hyperlipidemia [58]. Rs11574358 was 
recently identified to be associated with traits related to 
ageing, including cardiovascular disease prevalence, 
systolic blood pressure, cancer prevalence, total 
cholesterol and cystatin C in serum (chronic kidney 
disease) [42,105]. Since we know that rs11574358 is 
associated with traits such as cardiovascular disease 
prevalence and systolic blood pressure and the 
polymorphism converts a serine to an alanine residue, 
and has been suggested to abolish the phosphoserine 
structure of the protein and potentially affect protein 
function [106];  it is possible that this SNP may exert an 
age-dependent effect on mortality by contributing to the 
effect or severity of  the most common cancer co-
morbidities. Alternative hypotheses could be that the 
polymorphism may be associated with cancer 
aggressiveness, tissue susceptibility to cancer invasion 
or to changes in other ageing processes that contribute 
to mortality. 
 
The second SNP of interest was rs4147918; this SNP 
was assigned to the GPX4 LAG in this analysis, but as 
SNPs were allowed to be ±60kb of a LAG, the SNP is 
actually located within the nearby ABCA7 (Entrez ID: 
10347), a member of the superfamily of ATP-binding 
cassette transporters that transport various molecules 
across extra- and intra-cellular membranes. Rs4147918 
induces a glutamine-to-arginine change in an exon of 
the ABCA7 gene. Although this SNP is considered 
tolerated (i.e. not considered deleterious to function), 
even a variant that can be tolerated, or a synonymous 
change that appears not to affect amino acid selection at 
all, could still affect protein function and disease 
susceptibility, particularly when combined with the 
ageing process [107–110].  ABCA7 is on chromosome 
19p13.3, the same chromosomal section as APOE, a 
gene that is well known to be associated with ageing 
and longevity related traits [12,21,91,111,112]. In 
ABCA7, seven SNPs (including rs4147918) are 
cholesterol-related and showed a significant association 
with Late Onset Alzheimer’s Disease [21], although 
little else is reported on the clinical effects caused by 
this polymorphism. Thus, it is possible that similar to 
rs11574358, if some of the most common chronic co-
morbidities among cancer patients include ischemic 
heart disease, hypertension and hyperlipidemia [58];  
and rs4147918 is known to be cholesterol-related and 
associated with the ageing process, then it is possible  
that this polymorphism may exert an effect on age-
dependent mortality by changing the severity of 
particular co-morbidities.  
 
There was one gene of interest for further analysis; 
SIRT3, with four SNPs (although the SNPs are in 
SIRT3, and two closely-related genes PSMD13 and 
BET1L). Interestingly, SIRT3 is known to be involved in 
both the cancer and ageing processes [113–115]. In 
addition, PSMD13 and SIRT3 share a promoter [116], 
and PSMD13, a proteasome subunit, is involved in the 
degradation of abnormal proteins, cellular senescence 
[85] and ageing [86] and variants in this gene have 
previously been associated with the onset of various 
cancers [87–89]. Thus, it is plausible that having a high 
number of variants in closely related genes could impact 
cancer progression in an age-dependent manner. 
  
There was one pathway of interest for potential further 
investigation; FoxO signalling. The ability of FoxO 
factors to induce cell cycle arrest, DNA repair and 
apoptosis makes them attractive candidates as tumour 
suppressors [117,118]. In addition, members of the 
FoxO pathway are known to affect ageing and longevity 
[117–119]. Thus, since having a high number of 
variants appears to negatively affect cancer survival and 
the pathway is known to play an important role in the 
aetiology of cancer and the ageing process, perhaps a 
high level of variation in this pathway affects mortality 
in an age-dependent manner; which should be 
considered further. 
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There are a number of limitations to this investigation. 
First, it was not possible to identify an ideal replication 
population, as the Framingham Human Gene Focussed 
Affy 50K array is a unique custom array. We did not 
consider cancer-specific deaths in this instance; due to 
lack of data (In the AESC full data set, there were 663 
causes of deaths recorded, 47 of these had cancer as a 
primary cause of death). Although all-cause mortality is 
a common end-point for many successful survival 
analyses [18,49,50,55], we acknowledge that the 
absence of data on cancer-specific deaths versus all 
other causes of death limits our ability to interpret our 
observations, and leads to more questions. It would be 
interesting in the future to do similar investigations with 
cancer-specific death data available, in order to tease 
apart the specific contribution that variants such as 
those described in this research are contributing to 
specifically cancer survival. 
 
As with all polymorphism-trait studies, it is possible 
that our SNPs of interest do not exert effects on 
mortality themselves, but are in high linkage 
disequilibrium with the ungenotyped SNPs of interest. 
Some of the effects observed in this analysis would 
appear to be quite modest; for example, the gene and 
pathway analyses exhibit modest effects (~2 fold 
increased risk of death in particular age groups).  
However, similarly-sized effects have been reported in 
other analyses which have provided fascinating insight 
into the impact of genetic variants on various survival 
patterns [12,18,74,120,121]. In addition, given the 
complex nature of longevity and ageing as traits and the 
known difficulties in identifying SNPs and genes 
associated with these traits in even much larger human 
studies that do not account for the ageing process [122], 
the identification of SNPs that display even modest 
effects on cancer survival differently with age warrant 
further attention. Finally, it is not clear why age-
dependent survival effects are generally observed in 
those diagnosed 65 to 79, rarely in those diagnosed 50 
to 64 and never in those diagnosed over the age of 80.  
To eliminate potential bias caused by unequal sample 
size, the Kaplan Meier curves were repeated, using the 
same number of individuals per genotype between and 
within age categories, and the Cox Model analyses were 
divided by sex and cohort. One potential reason for a 
lack of observation in diagnosed >80 group could be 
that the overall mortality rate in the older population is 
such that more individuals die of unrelated causes, and 
so die with cancer but not due to cancer.  However, this 
does not explain the lack of observation in the 
diagnosed 50 to 64 group. In addition, Kulminski et al. 
(2014) similarly demonstrated that there is a significant 
adverse effect of the e4 allele on survival that is limited 
to women with a moderate lifespan (70-95 years); i.e. 
an effect was also not observed in the young (<70 years) 
or extremely old (>95 years) age categories. They 
suggested that possible reasons for these observations 
could include the buffering mechanisms by other genes 
[123] and/or the environmental modulations of genetic 
effects [124]. Therefore, an interesting open question 
arising from this work is why some variants affect 
survival in certain age groups, but not in others. 
 
In summary, this investigation suggests that the APOE 
variant identified by Kulminski et al. [12] may not be 
the sole variant that affects cancer survival in an age-
dependent manner. This study is the first exploratory 
systematic investigation to identify SNPs, genes and 
pathways that differentially affect mortality depending 
on the age of diagnosis, whose findings need to be 
independently validated in a suitable population, once 
such a population arises in the future. If corroborated, 
such information would provide potential targets for 
further exploration as prognostic biomarkers and 
individualised therapies in the post-genomic era. Given 
that we live in a greying population, and the majority of 
tumours are diagnosed in aged patients, such knowledge 
will be an invaluable tool advancing the field of 
geriatric oncology. 
 
MATERIALS AND METHODS 
 
Study population: the Framingham Heart Study 
 
The Framingham Heart Study (FHS) [36] comprises 
5,209 respondents aged 28-62 at baseline who have 
been biennially examined for almost 60 years. The 
Framingham Heart Study Offspring (FHSO) 
respondents (N=5,124) aged 5-70 at baseline were 
biological descendants (N=3,514), their spouses 
(N=1,576) and adopted offspring (N=34) of the FHS 
participants who were examined about every four years 
at nine visits. The study design has been detailed 
previously [39,40]. Phenotypic data was collected 
through FHS clinic examinations, hospital admission 
surveillances and monitoring death registries. 
Biospecimens were mostly collected in the late 1980s 
and through the 1990s from surviving participants [12]. 
The FHS data are available from the NIH SHARe 
through dbGaP [41] (accession number 
phs000007.v29.p10). 
 
Assembly of cancer and comorbidity phenotypic 
data set 
 
As described in the Results, two cancer data sets were 
assembled based on tumour topography for all patients 
that were first diagnosed with cancer over the age of 50 
and were not diagnosed solely via death cert: (1) All 
cancer except skin cancer (AESC; n=1,194) and (2) All 
cancer except skin and sex cancer (AESSC; n=867). 
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Skin cancer is commonly not considered in similar 
analyses (for example, [12,42]) due to accurate 
diagnosis difficulties that may affect survival times [43–
48]. Sex-related cancers were subsequently also 
removed to examine survival differences from cancers 
that are common to both sexes, as conducted in [12]. 
All-cause mortality is being considered in this analysis, 
this has been a common end-point for many successful 
survival analyses [17,49,50].  The data was right-
censored for the Kaplan Meier analysis. If date of death 
was not available, the date of last contact was used. 
 
Factors that may affect survival were considered. 
Comorbidities (i.e. additional diseases that co-occur 
with a primary disease of interest) can affect cancer 
diagnosis [51], treatment [52–54] and prognosis [55–
57]. The co-morbidities included in our analysis were: 
cerebrovascular disease, diabetes, congestive heart 
failure, dementia, myocardial infarction and subsequent 
cancer diagnoses; some of which are the most common 
co-morbidities in cancer [2,58,59]. Each individual was 
classified as having a low (0-2), medium (3-4) or high 
(5-6) number of co-morbidities. A tumour grade (1-4) 
was also assigned to each tumour. 
 
Assembly and quality filtering of the genetic data set 
 
The FHS Affymetrix 50K Human Gene Focused 
microarray was employed in this study. Quality control 
filtering was conducted as in [42] using PLINK v. 1.9 
[60]: SNPs were removed if they exhibited Hardy 
Weinberg P values <10-2, >10% missingness, >2% 
Mendel errors, <2% Minor Allele Frequency (MAF) or 
were located on a sex chromosome. Using PLINK, a 
LD analysis was also conducted between SNPs by 
calculating pair-wise r2 statistics for founders only, 
SNPs in high LD (i.e. r2 > 0.9) were removed.  
 
A set of 298 human LAGs (http://genomics.senescence. 
info/genes/human.html; Table S1b) and 83 human 
homolog to mouse genes (http://genomics.senescence 
.info/genes/models.html; Table S1c) were obtained 
from GenAge Build 17 [65]. Once the two data sets (i.e. 
human, and human homolog to mouse) were combined 
and redundant genes were removed, 316 putative LAGs 
remained (Table S1d). The location of each gene was 
retrieved from Ensembl [66], and SNPs located within 
±60kb of each putative LAG were extracted, similar to 
[42,67]. 880 SNPs were putatively identified as ageing-
related using this method, covering 245 of the 316 
genes in the data set (Table S1e). SNPs were 
subsequently assigned to the 245 LAGs; as described in 
the Results, a LAG could have one, two or more than 
two SNPs assigned to it. Third, SNPs were assigned to 
LAG pathways. A set of 69 pathways considered related 
to ageing process given their known involvement in 
ageing related processes were extracted from the KEGG 
database v. 74 [70] and 18 pathways that had at least 10 
genes and 10% overlap between the pathway genes and 
the set of longevity associated genes in this analysis 
were extracted [70] (Table S1g).  
 
Statistical analyses: the Kaplan Meier Estimator and 
Cox Proportional Hazards Model 
 
A KM curve was constructed for each 
SNP/gene/pathway of interest using the “survival” 
package v. 2.38 [71] in R v. 3.2.2 [72]. A Log Rank 
Test [73] subsequently examined the null hypothesis 
that there is no difference between the populations in 
the probability of an event (in this case, death) 
occurring at a time point.  Robustness of the constructed 
Kaplan Meier curves were examined by repeating the 
analysis twice: (1) Using equal number of wild type and 
variant genotypes and (2) Once the data set was divided 
by cohort (i.e. original and offspring cohorts) and sex 
(i.e. males and females). 
 
The KM Estimator and Log Rank Test do not allow 
other explanatory variables to be considered when 
estimating the survival differences between two groups. 
Thus, for SNPs, genes and pathways that displayed 
initial survival differences using the KM approach, a 
Cox Proportional Hazard Regression Model modelled 
survival as a function of genotype, sex, comorbidity 
status, cancer grade and cohort, implemented in the 
“coxme” package v. 2.2.3 [71] in R v. 3.2.2 [72]. 
Schoenfield residuals were used to test whether the 
proportional hazards assumption of the model were met, 
and only models with P values >0.05 were considered 
valid. As a result of non-proportionality, the models 
were stratified by sex, comorbidity status, cancer grade 
and cohort, similar to what has been conducted in other 
studies [74–76]. Genotypes were treated as categorical 
variables. In addition, a multivariate kinship frailty 
model implemented in the kinship package 
(http://cran.r-project.org/web/packages/kinship/) in R 
was incorporated to account for any familial 
relationships within the FHS [39,77].  Missing grade 
and genotypic information was imputed with the widely 
used multiple imputation method [78–81], implemented 
in MICE v. 2.25  [82]. For the Cox Model, in the SNP 
analysis, the hazard ratio (HR) describes the increase 
(or decrease) risk of death in the Var allele, compared to 
the WT allele. In the gene-level analysis, the risk of 
each genotype group is being compared to either the 
WT_WT allele (for those genes with two SNPs) or 
possessing a high number of WT alleles (for those 
genes with >2 SNPs). In the pathway analysis, the risk 
of each genotype group is being compared to those 
individuals with a high number of WT alleles.  
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To examine the robustness of the Cox Model, we 
repeated the analysis twice: (1) By adjusting the model 
for all of the factors instead of stratification (i.e. cohort, 
sex, grade, co-morbidities and, for the SNP analysis, 
other SNPs of interest from the Kaplan Meier analysis) 
and (2) Once the data was split by sex (i.e. male and 
female) and cohort (i.e. original and offspring), and 
using an equal number of individuals per genotype and 
age category. A Benjamini-Hochberg False Discovery 
Rate (FDR) was calculated across the AESC and 
AESSC data sets, all age brackets and all SNPs, genes 
or pathways of interest. In addition, once the data was 
divided based on cohort (i.e. original and offspring) or 
sex, the FDR was conducted across all conditions (i.e. 
male, female, original and offspring). A FDR <0.05 was 
considered statistically significant.  
 
Replication analysis in an independent population 
 
A replication population was selected based on the 
combination of two cohorts. In the Atherosclerosis Risk 
in Communities Study (ARIC) [83], the study 
participants (aged 45-64 at baseline in 1987) were 
randomly selected and recruited at four field centres 
across the U.S. We used data from four available 
examinations. Genotyping in 12,771 ARIC participants 
(N=9,633 Caucasians) was conducted using Affymetrix 
6.0 array (1,000K SNPs). For the Cardiovascular Health 
Study (CHS) [84], the main cohort of the CHS 
participants (N=5,201 Caucasians) aged 65+ years at 
baseline in 1989 was examined annually through 1999. 
The CHS clinic exams ended in June 1999. After June 
1999 two phone calls per year to participants collected 
information on incidence of diseases and death. Deaths 
also were ascertained through surveillance and at semi-
annual contacts. SNPs for the present study were 
selected from the Candidate Gene Association Resource 
(CARe) that included records for 5,531 CHS 
participants. This investigation combined the two 
studies to carry out our analyses, restricting to partici-
pants of European descent. 
 
Availability of data and materials 
 
The data generated during this study (for example 
survival study results) is available in the supplementary 
material. The Framingham SHARe data used for the 
analyses described in this manuscript were obtained 
through dbGaP 
(accession number phs000007.v29.p10). The URL for 
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